A compound according to Formula: wherein: R 1 is hydrogen, halogen, (C 1 -C 6)alkyl, halo(C 1 -C 6)alkyl, (C 3 -C 6)cycloalkyl, hydroxyl, (C 1 -C 6)alkoxy, halo(C 1 -C 6)alkoxy, (C 3 -C 6)cycloalkoxy, amino, ((C 1 -C 6)alkyl)amino-, or ((C 1 -C 6)alkyl)((C 1 -C 6)alkyl)amino-; each R 2 is independently selected from the group consisting of halogen, (C 1 -C 6)alkyl, halo(C 1 -C 6)alkyl, (C 3 -C 6)cycloalkyl, cyano, hydroxyl, (C 1 -C 6)alkoxy, halo(C 1 -C 6)alkoxy, (C 3 -C 6)cycloalkoxy, amino, ((C 1 -C 6)alkyl)amino-, and ((C 1 -C 6)alkyl)((C 1 -C 6)alkyl)amino-; R 3 is phenyl or 5- or 6-membered heteroaryl, each of which is optionally substituted with one to three substituents independently selected from halogen, (C 1 -C 6)alkyl, halo(C 1 -C 6)alkyl, (C 3 -C 6)cycloalkyl, cyano, 5- or 6-membered heteroaryl, -OR 4, and -CONR 5 R 6; wherein said (C 1 -C 6)alkyl is optionally substituted by cyano, hydroxyl, (C 1 -C 4)alkoxy, halo(C 1 -C 4)alkoxy, or -NR 5 R 6; and wherein said 5- or 6-membered heteroaryl substituent is optionally substituted by halogen, (C 1 -C 4)alkyl, or halo(C 1 -C 4)alkyl; R 4 is hydrogen, (C 1 -C 6)alkyl, halo(C 1 -C 6)alkyl, (C 3 -C 6)cycloalkyl, or 4- to 6-membered heterocycloalkyl; wherein said (C 1 -C 6)alkyl is optionally substituted by cyano, hydroxyl, (C 1 -C 4)alkoxy, halo(C 1 -C 4)alkoxy, or -NR 5 R 6; and wherein said (C 3 -C 6)cycloalkyl is optionally substituted with one or two substituents independently selected from (C 1 -C 4)alkyl, halo(C 1 -C 4)alkyl, hydroxyl, hydroxy(C 1 -C 4)alkyl, (C 1 -C 4)alkoxy, and halo(C 1 -C 4)alkoxy; and wherein said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from (C 1 -C 4)alkyl and halo(C 1 -C 4)alkyl; R 5 and R 6 are each independently selected from the group consisting of hydrogen, (C 1 -C 4)alkyl, and halo(C 1 -C 4)alkyl; or R 5 and R 6 taken together with the nitrogen to which they are attached represent a 5- or 6- membered saturated ring, optionally containing an additional heteroatom selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted by halogen, (C 1 -C 4)alkyl, or halo(C 1 -C 4)alkyl; and n is 0, 1, or 2; or a pharmaceutically acceptable salt thereof. R 1 is hydrogen, halogen, (C 1 -C 6)alkyl, halo(C 1 -C 6)alkyl, (C 3 -C 6)cycloalkyl, hydroxyl, (C 1 -C 6)alkoxy, halo(C 1 -C 6)alkoxy, (C 3 -C 6)cycloalkoxy, amino, ((C 1 -C 6)alkyl)amino-, or ((C 1 -C 6)alkyl)((C 1 -C 6)alkyl)amino-; each R 2 is independently selected from the group consisting of halogen, (C 1 -C 6)alkyl, halo(C 1 -C 6)alkyl, (C 3 -C 6)cycloalkyl, cyano, hydroxyl, (C 1 -C 6)alkoxy, halo(C 1 -C 6)alkoxy, (C 3 -C 6)cycloalkoxy, amino, ((C 1 -C 6)alkyl)amino-, and ((C 1 -C 6)alkyl)((C 1 -C 6)alkyl)amino-; R 3 is phenyl or 5- or 6-membered heteroaryl, each of which is optionally substituted with one to three substituents independently selected from halogen, (C 1 -C 6)alkyl, halo(C 1 -C 6)alkyl, (C 3 -C 6)cycloalkyl, cyano, 5- or 6-membered heteroaryl, -OR 4, and -CONR 5 R 6; wherein said (C 1 -C 6)alkyl is optionally substituted by cyano, hydroxyl, (C 1 -C 4)alkoxy, halo(C 1 -C 4)alkoxy, or -NR 5 R 6; and wherein said 5- or 6-membered heteroaryl substituent is optionally substituted by halogen, (C 1 -C 4)alkyl, or halo(C 1 -C 4)alkyl; R 4 is hydrogen, (C 1 -C 6)alkyl, halo(C 1 -C 6)alkyl, (C 3 -C 6)cycloalkyl, or 4- to 6-membered heterocycloalkyl; wherein said (C 1 -C 6)alkyl is optionally substituted by cyano, hydroxyl, (C 1 -C 4)alkoxy, halo(C 1 -C 4)alkoxy, or -NR 5 R 6; and wherein said (C 3 -C 6)cycloalkyl is optionally substituted with one or two substituents independently selected from (C 1 -C 4)alkyl, halo(C 1 -C 4)alkyl, hydroxyl, hydroxy(C 1 -C 4)alkyl, (C 1 -C 4)alkoxy, and halo(C 1 -C 4)alkoxy; and wherein said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from (C 1 -C 4)alkyl and halo(C 1 -C 4)alkyl; R 5 and R 6 are each independently selected from the group consisting of hydrogen, (C 1 -C 4)alkyl, and halo(C 1 -C 4)alkyl; or R 5 and R 6 taken together with the nitrogen to which they are attached represent a 5- or 6- membered saturated ring, optionally containing an additional heteroatom selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted by halogen, (C 1 -C 4)alkyl, or halo(C 1 -C 4)alkyl; and n is 0, 1, or 2; or a pharmaceutically acceptable salt thereof.